AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$LQDA

Moomaw Scott sold $252K of LQDA

Moomaw Scott (Chief Commercial Officer) sold 8,863 shares of Liquidia Corp (LQDA) at $28.48 ($0.25M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moomaw Scott
Published Oct 14, 2026, 12:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosed sale is the primary new fact; no other material news is presented.

02

Market read

A modest insider sale by a senior officer, likely to cause limited short‑term price impact.

03

What to watch

Potential upcoming corporate developments could have prompted the timing of the sale.

Relevance 3/10Novelty 3/10Timing: after-hours

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Chief Commercial Officer sold 8,863 shares for $252K via a 10b5-1 plan, reducing his holdings to 181,487 shares.

Expected impact

likely pressure as the market prices in the insider sell.

Evidence & confidence

C-suite insider sale, even modest, can be interpreted as reduced confidence and may prompt short-term downside.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The sale may be routine under a pre‑arranged plan and not reflect negative sentiment.

Key entities

  • person
    Moomaw Scott

    Chief Commercial Officer of Liquidia Corp.

  • company
    Liquidia Corp

    Biopharmaceutical company listed on NASDAQ under LQDA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

zacks.com
$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

investing.com
$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

finance.yahoo.com
$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

finance.yahoo.com